PKTX (ProtoKinetix) Total Liabilities: $0.23 Mil (As of Sep. 2025)


What is ProtoKinetix Total Liabilities?

ProtoKinetix PKTX +36.54% Total Liabilities is $0.23 Mil as of Sep. 2025. The stock has 1 warning sign investors should review.

ProtoKinetix's Total Liabilities for the quarter that ended in Sep. 2025 was $0.23 Mil.

ProtoKinetix's quarterly Total Liabilities declined from Mar. 2025 ($0.15 Mil) to Jun. 2025 ($0.15 Mil) but then increased from Jun. 2025 ($0.15 Mil) to Sep. 2025 ($0.23 Mil).

ProtoKinetix's annual Total Liabilities increased from Dec. 2022 ($0.04 Mil) to Dec. 2023 ($0.05 Mil) and increased from Dec. 2023 ($0.05 Mil) to Dec. 2024 ($0.12 Mil).

ProtoKinetix Total Liabilities Historical Data

* Premium members only.

The historical data trend for ProtoKinetix's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProtoKinetix Total Liabilities Chart

ProtoKinetix Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.09 0.04 0.05 0.12

ProtoKinetix Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.12 0.15 0.15 0.23

ProtoKinetix Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ProtoKinetix's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.124+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.12

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=0.466-0.342
=0.12

ProtoKinetix's Total Liabilities for the quarter that ended in Sep. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.227+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.23

Total Liabilities=Total Assets (Q: Sep. 2025 )-Total Equity (Q: Sep. 2025 )
=0.478-0.25
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $0.23 Mil mean?
ProtoKinetix (PKTX) has a Total Liabilities of $0.23 Mil as of Sep. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ProtoKinetix and its competitors.
Is ProtoKinetix's Total Liabilities too high?
ProtoKinetix's current Total Liabilities is $0.23 Mil.
How does ProtoKinetix's Total Liabilities compare to BBLG and VRAX?
ProtoKinetix's Total Liabilities of $0.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ProtoKinetix and its competitors. ProtoKinetix's current Total Liabilities is $0.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProtoKinetix stock overvalued right now?
ProtoKinetix (PKTX) has a current Total Liabilities of $0.23 Mil. The current Total Liabilities is $0.23 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For ProtoKinetix (PKTX), the current Total Liabilities is $0.23 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProtoKinetix Business Description

Address 109 W Main Street, Dalton, OH, USA, 44618
ProtoKinetix Inc is a research and development stage biotechnology company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins). The AFGP is a compound produced by fish, insects, reptiles, bacteria, and plants that enable survival in freezing temperatures. The company also develops AFGP applications which include regenerative medicine issues including harvesting, processing, storage, and transplanting cells, tissues, and organs and treatments for chronic inflammatory conditions and diseases caused by stress factors, including UV radiation, oxidation, and cryopreservation and hydrogen peroxide.